1. Home
  2. COCH vs SCYX Comparison

COCH vs SCYX Comparison

Compare COCH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.67

Market Cap

51.0M

Sector

Finance

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.70

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COCH
SCYX
Founded
1995
1999
Country
United States
United States
Employees
47
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
42.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
COCH
SCYX
Price
$0.67
$3.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$6.00
$3.00
AVG Volume (30 Days)
327.4K
79.3K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$1.58
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.57
52 Week High
$1.89
$5.62

Technical Indicators

Market Signals
Indicator
COCH
SCYX
Relative Strength Index (RSI) 42.69 45.87
Support Level $0.64 $3.68
Resistance Level $0.74 $5.10
Average True Range (ATR) 0.06 0.37
MACD -0.01 -0.15
Stochastic Oscillator 10.90 15.29

Price Performance

Historical Comparison
COCH
SCYX

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: